The preplanned liquidation happened and PwC could only sell the Canadian tangible assets, they had no access to anything else, then there was the Bioamber French sale S A.S. that was sold in France where the company originated and all the IP was transferred to Bioamber Inc, than during restructuring when it was dismissed from chapter 11, Eno not PwC sold the entire company, which is the investment in Bioamber for acquisition to include the share purchase after the restructuring which could be a delay because Bioamber had leased their patents with an expiration date, the offer of the share price is still under seal with confidentiality, what PwC has done they combined all transactions into one, there is three transactions, the sale of Bioamber inc had to include the French sale, lawyers are here to still try to confuse Bioamber's shareholders to give up their shares, another mention is the buyout of Mitsui had to happen for Eno to sell Bioamber inc as a whole company with no attachments,so this should be huge $22+/share into a merger
